количество зарегистрированных пользователей: 68850

Rumedo Медицинский образовательный портал

МЕДИЦИНСКИЙ ОБРАЗОВАТЕЛЬНЫЙ ПОРТАЛ

Академия инновационного образования

БИБЛИОТЕКА

По категориям

По специальностям

  • Зарубежные материалы

    Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997

    Дата публикации 19.11.2020
    World Health Organization
    WHO/NUT/NCD/98.1

    WHO Consultation on Obesity (‎1997: Geneva, Switzerland)‎, World Health Organization. Division of Noncommunicable Diseases & World Health Organization. Programme of Nutrition, Family and Reproductive Health. (‎1998)‎. Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization.

    Подробнее

    700

  • Зарубежные материалы

    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

    Дата публикации 19.11.2020
    E.A. Bohula, S.D. Wiviott, D.K. McGuire, S.E. Inzucchi, J. Kuder, K.A. Im, C.L. Fanola, A. Qamar, C. Brown, A. Budaj, A. Garcia‑Castillo, M. Gupta, L.A. Leiter, N.J. Weissman, H.D. White, T. Patel, B. Francis, W. Miao, C. Perdomo, S. Dhadda, M.P. Bonaca, C.T. Ruff, A.C. Keech, S.R. Smith, M.S. Sabatine, and B.M. Scirica, for the CAMELLIA–TIMI 61 Steering Committee and Investigators
    N Engl J Med 2018;379:1107-17. DOI: 10.1056/NEJMoa1808721

    Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.

    Подробнее

    781

  • Зарубежные материалы

    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 19.11.2020
    S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn, M.G. Silverman, T.A. Zelniker, J.F. Kuder, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, C.T. Ruff, I.A.M. Gause‑Nilsson, M. Fredriksson, P.A. Johansson, A.-M. Langkilde, and M.S. Sabatine, for the DECLARE–TIMI 58 Investigators
    N Engl J Med 2019;380:347-57. DOI: 10.1056/NEJMoa1812389

    The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.

    Подробнее

    773

  • Зарубежные материалы

    2018 ESC/ESH Guidelines for the management of arterial hypertension

    Дата публикации 19.11.2020
    Bryan Williams* (ESC Chairperson) (UK), Giuseppe Mancia* (ESH Chairperson) (Italy), Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel Burnier (Switzerland), Denis L. Clement (Belgium), Antonio Coca (Spain), Giovanni de Simone (Italy), Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), Luis Ruilope (Spain), Alberto Zanchetti† (Italy), Mary Kerins (Ireland), Sverre E. Kjeldsen (Norway), Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y. H. Lip (UK), Richard McManus (UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland), Roland E. Schmieder (Germany), Evgeny Shlyakhto (Russia), Costas Tsioufis (Greece), Victor Aboyans (France), and Ileana Desormais (France)
    European Heart Journal (2018) 39, 3021–3104 doi:10.1093/eurheartj/ehy339

    Подробнее

    758

  • Зарубежные материалы

    The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes

    Дата публикации 19.11.2020
    Victor J. Dzau, MD; Elliott M. Antman, MD; Henry R. Black, MD; David L. Hayes, MD; JoAnn E. Manson, MD, DrPH; Jorge Plutzky, MD; Jeffrey J. Popma, MD; William Stevenson, MD
    DOI: 10.1161/CIRCULATIONAHA.106.655688

    Fifteen years ago, a panel of experts representing the full spectrum of cardiovascular disease (CVD) research and practice assembled at a workshop to examine the state of knowledge about CVD. The leaders of the workshop generated a hypothesis that framed CVD as a chain of events, initiated by a myriad of related and unrelated risk factors and progressing through numerous physiological pathways and ...

    Подробнее

    626

  • Зарубежные материалы

    Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

    Дата публикации 19.11.2020
    The New England Journal of Medicine
    nejm.org on October 23, 2020.

    The extent to which diabetes mellitus or hyperglycemia is related to risk of death from cancer or other nonvascular conditions is uncertain.

    Подробнее

    706

  • Зарубежные материалы

    The effects of postnatal health education for mothers on infant care and family planning practices in Nepal: a randomised controlled trial

    Дата публикации 19.11.2020
    Alison Bolam, Dharma S Manandhar, Purna Shrestha, Matthew Ellis, Anthony M de L Costello
    BMJ VOLUME 316 14 MARCH 1998

    Mothers in groups A and B (received health education at birth) were slightly more likely to use contraception at six months after birth compared with mothers in groups C and D (no health education at birth) (odds ratio 1.62, 95% confidence interval 1.06 to 2.5). There were no other significant differences between groups with regards to infant feeding, infant care, or immunisation.

    Подробнее

    595

  • Статьи

    Сахарный диабет 2-го типа и хроническая сердечная недостаточность – «Несладкая парочка»

    Дата публикации 19.11.2020
    И.Г. Починка, ФГБОУ ВО «Нижегородская государственная медицинская академия»
    № 6 (51) ноябрь 2017 МЕДИЦИНСКИЙ АЛЬМАНАХ

    Подробнее

    695

  • Зарубежные материалы

    Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study

    Дата публикации 19.11.2020
    Frederik Persson MD, DMSc, Thomas Nyström MD PhD, Marit E. Jørgensen MD PhD, Bendix Carstensen MSc, Hanne L. Gulseth MD PhD, Marcus Thuresson PhD, Peter Fenici MD PhD, David Nathanson MD PhD, Jan W. Eriksson MD PhD, Anna Norhammar MD PhD, Johan Bodegard MD PhD, Kåre I. Birkeland MD PhD
    DOI: 10.1111/dom.13077

    After matching, a total of 40 908 patients with T2D were identified as new users of dapagliflozin (n = 10 227) or a DPP-4 inhibitor (n = 30 681). The groups were well balanced at baseline; their mean age was 61 years and 23% had CV disease. The mean follow-up time was 0.95 years, with a total of 38 760 patient-years. Dapagliflozin was associated with a lower risk of MACE, HHF and all-cause mortal ...

    Подробнее

    848

  • Зарубежные материалы

    Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

    Дата публикации 19.11.2020
    Peter Gæde, M.D., D.M.Sc., Henrik Lund-Andersen, M.D., D.M.Sc., Hans-Henrik Parving, M.D., D.M.Sc., and Oluf Pedersen, M.D., D.M.Sc.
    N Engl J Med 2008;358:580-91.

    Intensified multifactorial intervention — with tight glucose regulation and the use of renin–angiotensin system blockers, aspirin, and lipid-lowering agents — has been shown to reduce the risk of nonfatal cardiovascular disease among patients with type 2 diabetes mellitus and microalbuminuria. We evaluated whether this approach would have an effect on the rates of death from any cause and from ca ...

    Подробнее

    666

  • Зарубежные материалы

    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

    Дата публикации 19.11.2020
    Eri T. Kato, MD, MPH, PhD et al
    Circulation. 2019;139:2528–2536. DOI: 10.1161/CIRCULATIONAHA.119.040130

    In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

    Подробнее

    725

  • Зарубежные материалы

    Pioglitazone Initiation and Subsequent Hospitalisation for Congestive Heart Failure

    Дата публикации 19.11.2020
    Andrew J. Karter, Ph.D., Ameena T. Ahmed, M.D., M.P.H., Jennifer Liu, M.P.H., Howard H. Moffet, M.P.H., and Melissa M. Parker, M.S.
    Diabet Med. 2005 August ; 22(8): 986–993. doi:10.1111/j.1464-5491.2005.01704.x.

    Thiazolidinediones (TZD) have been associated with an expansion in plasma volume and the development of peripheral oedema. A recent study reported an association between the use of TZDs and development of congestive heart failure (CHF). The objective of this study was todetermine if short-term use of pioglitazone, a TZD, is associated with increased risk of CHF hospitalisation in a well-character ...

    Подробнее

    701

  • Зарубежные материалы

    Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial

    Дата публикации 19.11.2020
    Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen, Trine Welløv Boesgaard, Morten Schou, Lars Videbæk, Ida Gustafsson, Allan Flyvbjerg, Henrik Wiggers, Lise Tarnow
    European Journal of Heart Failure (2017) 19, 69–77 doi:10.1002/ejhf.657

    In patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF), angiotensin-converting enzyme inhibitors, beta-blockers, and spironolactone reduce mortality and improve LVEF. However, long-term survival and quality of life remain markedly impaired, especially in patients with diabetes. We therefore need new, safe treatment modalities that can improve CHF symptom ...

    Подробнее

    810

  • Зарубежные материалы

    Risk Factors for Congestive Heart Failure in US Men and Women

    Дата публикации 19.11.2020
    Jiang He, MD, PhD; Lorraine G. Ogden, MS; Lydia A. Bazzano, PhD; et al
    Arch Intern Med. 2001;161(7):996-1002. doi:10.1001/archinte.161.7.996

    The incidence of congestive heart failure (CHF) has been increasing steadily in the United States during the past 2 decades. We studied risk factors for CHF and their corresponding attributable risk in the First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study

    Подробнее

    598

  • Зарубежные материалы

    CV Protection in the EMPA-REG OUTCOME Trial: A“Thrifty Substrate” Hypothesis

    Дата публикации 19.11.2020
    Ele Ferrannini, Michael Mark, Eric Mayoux
    Diabetes Care 2016;39:1108–1114 | DOI: 10.2337/dc16-0330

    The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trialdmo ...

    Подробнее

    816